Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorthamber Regulatory News (NAR)

Share Price Information for Northamber (NAR)

Share Price is delayed by 15 minutes
Get Live Data
26.00    0.00 (0.00%)
Bid:
24.00
Ask:
28.00
Spread: 4.00 (16.667%)
Market Cap: £7.05m
NAR Live PriceLast checked at - London Stock Exchange

Intraday Northamber Share Chart

Interim Management Statement

17 Nov 2011 15:54

RNS Number : 3200S
Northamber PLC
17 November 2011
 



17 November 2011

 

Northamber plc

Interim Management Statement

 

The results of the strategic refocus of the business model in my last update to shareholders and the repositioning of our vendor offerings, are starting to bear fruit. Sales in Q1 of the current financial year improved by some 9% over the Q4 sales to 30 June 2011.

 

However, as widely published, all volume product sectors continue to suffer significantly from reducing demand and resultant over-supply. Context's market analysis on European I.T. distribution stated that Q3 demand had decreased by 18% over 2010.

 

On our own volume product portfolio, we were not immune to the lower levels of demand. Consequential oversupply and commensurate vendor destocking actions adversely affected our overall margins. Despite having taken avoiding actions and our areas of success, overall gross profit margins of 6.5% for our July to September Q1 compared with 7.0% for last year as a whole.

 

The combination of de-positioning the empty-revenue portion of our volume portfolio offerings and the wider economic downturn resulted in a 29% reduction in total sales in Q1 to 30 September 2011 of this financial year compared with Q1 last year.

 

The effects of the significant falls in selling prices per unit of the oversupplied volume products has resulted in our costs of sale being a greater daily management challenge.

 

As always we operate very strict cost controls on every aspect of the business. Whilst continuing to work to bring the cost ratios back into line with our needs and expectations, since the start of 2011 the underlying uncertainties have presented additional challenges to the business.

 

Some pre-emptive significant cost savings have already been implemented and will be recognised in the second half of the current financial year, and beyond. However, the unabated pressures of the on-going challenges are keeping this subject at the forefront of our attentions.

 

The extent of the volume product sector downturn can best be assessed at the operating level where the loss in Q1 to 30 September 2011 of 1.6% of sales, compared with a profit of 0.4% of sales in Q1 last year and a near break-even level for last year as a whole.

 

After buying another 150,000 ordinary shares for treasury at a cost of £86,155, we continue to maintain a very high level cash balances, with zero borrowings. The cash balance at the end of Q1 this year was £9.08 million compared with £10.7 million at 30 June. Whilst the rates of interest remain at a consistent low level, the income from these balances is minimal.

 

Net Assets per share at 30 September 2011 were 85.2 pence per share, compared with 86.5 pence per share at the end of June 2011.

 

For the present, there is no clear indication of any early improvement in the industry outlook. Hopefully when the overstocking situation is resolved there may be a return to a more rational balance of product and pricing. In the meantime we can only continue to operate as efficiently and effectively as we can.

 

For further information please contact:

 

Northamber plc 020 8296 7000

David Phillips

 

FoxDavies Capital 020 3463 5000

Barry Saint

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDKODPPBDDNDD
Date   Source Headline
26th Nov 202112:07 pmRNSPosting of Annual Report
19th Nov 20217:00 amRNSFinal Results
6th Apr 20217:00 amRNSBoard Appointments
10th Mar 202112:31 pmRNSResult of AGM
22nd Feb 20212:06 pmRNSSecond Price Monitoring Extn
22nd Feb 20212:00 pmRNSPrice Monitoring Extension
12th Feb 20217:00 amRNSHalf-year Report
11th Feb 20216:27 pmRNSAnnual Financial Report - Amendment
11th Feb 20215:17 pmRNSAnnual Financial Report
10th Feb 202111:14 amRNSTransfer of Shares to Director
29th Jan 20215:05 pmRNSFinal Results
22nd Dec 20202:30 pmRNSUpdate on Annual Report and Trading
28th Oct 20207:00 amRNSAppointment of Chairman
13th Oct 202012:29 pmRNSHolding(s) in Company
13th Oct 202012:27 pmRNSHolding(s) in Company
27th Aug 20207:00 amRNSAppointment of Managing Director
3rd Aug 20207:00 amRNSChange of Adviser
14th May 20209:00 amRNSChange of Auditor
11th May 20209:32 amRNSHolding(s) in Company
19th Mar 20205:02 pmRNSHolding(s) in Company
4th Mar 20205:00 pmRNSTransaction in Own Shares
3rd Mar 20207:00 amRNSHalf-year Report
11th Feb 20202:49 pmRNSHolding(s) in Company
6th Feb 20203:50 pmRNSReplacement: Board change
6th Feb 20203:00 pmRNSBoard change
3rd Feb 20207:00 amRNSCompletion of AVM Acquisition
18th Dec 20192:00 pmRNSPotential Acquisition
18th Dec 20191:15 pmRNSResult of AGM
13th Dec 201911:00 amRNSPurchase of Warehouse Facility
5th Dec 20195:00 pmRNSStatement regarding David Phillips
25th Nov 201910:00 amRNSAnnual Financial Report
14th Nov 20197:00 amRNSFinal Results
1st Jul 20194:44 pmRNSSecond Price Monitoring Extn
1st Jul 20194:38 pmRNSPrice Monitoring Extension
1st Jul 20192:00 pmRNSSale of Warehouse Facility for £16.4 million
8th Mar 20197:00 amRNSHalf-year Report
27th Feb 20197:00 amRNSDirectorate Change
14th Dec 20182:15 pmRNSResult of AGM
30th Nov 20181:04 pmRNSTransaction in Own Shares
14th Nov 20187:00 amRNSPosting of Annual Report
20th Sep 20187:00 amRNSFinal Results
17th Aug 20183:23 pmRNSTransaction in Own Shares
25th May 201811:10 amRNSHolding(s) in Company
17th May 201812:44 pmRNSHolding(s) in Company
14th Feb 20187:00 amRNSHalf-year Report
12th Dec 20174:18 pmRNSResult of AGM
17th Nov 201710:12 amRNSAnnual Financial Report
3rd Nov 20177:00 amRNSFinal Results
27th Mar 20177:00 amRNSHalf-year Report
18th Nov 20168:30 amRNSPosting of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.